NPC
CLDX icon

National Planning Corporation’s Celldex Therapeutics CLDX Stock Holding History

National Planning Corporation’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-3,900
Closed -$167K – 132
2017
Q3 		$167K Sell
3,900
-203
-5% -$7.61K 0.01% 645
2017
Q2 		$158K Sell
4,103
-226
-5% -$10K 0.01% 704
2017
Q1 		$218K Buy
4,329
+667
+18% +$34.7K 0.02% 613
2016
Q4 		$185K Sell
3,662
-21
-0.6% -$1.2K 0.01% 637
2016
Q3 		$182K Hold
3,683
– – 0.01% 597
2016
Q2 		$251K Buy
3,683
+110
+3% +$6.98K 0.02% 540
2016
Q1 		$187K Hold
3,573
– – 0.02% 584
2015
Q4 		$389K Sell
3,573
-917
-20% -$200K 0.03% 473
2015
Q3 		$880K Sell
4,490
-13
-0.3% -$3.68K 0.08% 233
2015
Q2 		$1.15M Buy
4,503
+3
+0.1% +$1.19K 0.1% 199
2015
Q1 		$1.64M Buy
4,500
+200
+5% +$71.5K 0.15% 140
2014
Q4 		$1.22M Buy
4,300
+300
+8% +$74.6K 0.09% 211
2014
Q3 		$827K Buy
+4,000
New +$872K 0.06% 287
2013
Q4 		– Sell
-2,043
Closed -$1.16M – 708
2013
Q3 		$1.16M Buy
+2,043
New +$701K 0.11% 196

Other funds holding CLDX

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

National Planning Corporation's CLDX Position: Q4 2017 in Review

National Planning Corporation sold out of Celldex Therapeutics (CLDX) in Q4 2017, closing a stake of 3,900 shares — an estimated $167K sold.

National Planning Corporation first reported a position in CLDX in Q3 2013 and held it in 14 quarters. The position peaked at $1.64M in Q1 2015. 135 funds tracked by Wall St. Rank hold CLDX as of Q4 2017.

  • National Planning Corporation reported no remaining Celldex Therapeutics position as of Q4 2017 after selling out during the quarter.
  • National Planning Corporation sold 3,900 Celldex Therapeutics shares in Q4 2017, an estimated $167K.
  • National Planning Corporation first reported a position in Celldex Therapeutics in Q3 2013 and held it in 14 quarters.
  • National Planning Corporation's Celldex Therapeutics position peaked at $1.64M in Q1 2015.
  • 135 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2017.

Based on National Planning Corporation's 13F filing for Q4 2017, filed 14 Feb 2018.